• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Your Heart in Flames

Neo Science Hub by Neo Science Hub
6 months ago
in Science News
0
Heart Flames

Inflammation as a Hidden Driver of Heart Disease

For decades, the dominant narrative of cardiovascular disease centred on cholesterol — a waxy villain clogging arteries, a problem to be solved by statins and dietary restraint. That narrative, while not wrong, has always been incomplete. Emerging from decades of painstaking research is a parallel and equally urgent story: chronic, low-grade inflammation may be as powerful a driver of heart attacks and strokes as any lipid panel your doctor has ever ordered.

The inflammatory hypothesis of cardiovascular disease did not arrive suddenly. As early as the 1990s, pathologists noted that atherosclerotic plaques — the fatty deposits that narrow arteries and rupture catastrophically — were not passive accumulations of lipid, but living sites of immune activity. White blood cells, cytokines, and inflammatory proteins such as C-reactive protein (CRP) were found embedded in these plaques, suggesting that the arterial wall was engaged in a chronic, smouldering battle with its own immune system.

The landmark CANTOS trial in 2017 provided the first decisive clinical proof. It demonstrated that canakinumab, a monoclonal antibody targeting interleukin-1β — a master inflammatory signalling molecule — reduced major adverse cardiovascular events in high-risk patients, independent of any change in cholesterol levels. The implications were seismic: inflammation was not merely a companion to cardiovascular risk, it was a cause.

High-sensitivity CRP (hsCRP) has since emerged as a biomarker of particular clinical weight. Research now shows that hsCRP is at least as strong a predictor of future cardiovascular events as traditional lipoproteins — a finding that has prompted the European Society of Cardiology’s 2024 Guidelines for Chronic Coronary Syndrome to formally recommend targeted anti-inflammatory therapy for patients with elevated residual inflammatory risk even when lipid levels are adequately controlled.

But the most dramatic development is the resurgence of a drug that has been used for centuries in a completely different context: colchicine. Derived from the autumn crocus and long employed to treat gout and pericarditis, low-dose colchicine (0.5 mg daily) has now been shown, through multiple rigorous randomised controlled trials including COLCOT and LoDoCo2, to significantly reduce the risk of myocardial infarction and other major cardiovascular events. A 2025 Cochrane systematic review incorporating data from 22,153 participants across eight studies confirmed with high certainty that low-dose colchicine reduces MI risk by approximately 26 percent.

The drug works by disrupting microtubule polymerisation in immune cells, inhibiting the NLRP3 inflammasome and downstream cytokine cascades, thereby dampening the precise inflammatory pathway that destabilises arterial plaques. It is taken orally, costs a fraction of newer biological therapies, and has a well-characterised safety profile, albeit requiring caution in patients with significant renal or hepatic dysfunction.

The US Food and Drug Administration approved low-dose colchicine for cardiovascular risk reduction in 2024, and the American Heart Association/American College of Cardiology has assigned it a Class 2a recommendation for patients with chronic stable coronary artery disease. Despite this, clinical uptake remains conspicuously limited — a gap that cardiologists and public health researchers are working urgently to close.

What makes the inflammation story particularly sobering is that it operates silently. Patients without elevated cholesterol, without hypertension, without diabetes — patients who believe themselves insulated from cardiac risk — may carry persistently elevated hsCRP, driven by sedentary lifestyles, chronic stress, subclinical infections, or metabolic dysfunction, and face a significantly elevated hazard that standard risk calculators fail to capture.

The prescription for the future is clear: routine hsCRP screening, not as an afterthought but as a standard of cardiovascular care, and swift deployment of affordable anti-inflammatory therapy where elevated inflammatory risk is confirmed. The inflammation hypothesis has graduated from hypothesis to evidence-based framework. The question now is not whether inflammation matters to the heart — it unquestionably does — but how quickly the global clinical community will integrate this knowledge into everyday practice. The fire in the arterial wall has been burning long before symptoms appear. Medicine must learn to read the smoke.

– Dr Srinayana Kavuri

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: featuredsciencenews
Neo Science Hub

Neo Science Hub

NEO SCIENCE HUB is envisaged as a Web Portal and E-Magazine to provide digital access to the cutting edge and advanced technology, hosted across the globe in all the disciplines of Science

Other Posts

Community health worker's table with a blood-pressure monitor and a glucometer on a rural veranda

24 Lakh New Cases Found: Andhra Pradesh’s Mass Screening Exposes the Hidden Scale of Hypertension and Diabetes

November 19, 2026
0
Illustration comparing a normal foetal spine with an open spina bifida defect

Surgery Before Birth: AIIMS Delhi Performs India’s First Open Foetal Repair of Severe Spina Bifida

November 19, 2026
0

When the Grid Blinks: Inside the Wave of Global Outages and AI-Driven Cyberattacks

The Science of Smart Warmth: Inside the Modern Electric Blanket

Sai Parenterals Strengthens Presence with Majority Stake Acquisition in Bian Therapeutics

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

Small Leaves, Small Particles: Microgreens Have the Evidence. Nano-Urea Is Still Earning It

A Crore and a Half Recharge Pits Later: What India’s Water Reforms Can, and Cannot, Teach the Global South

Next Post
AI Digital Disruption

Math Long Resisted a Digital Disruption… AI Is Poised to Change That

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
8

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist